CTNM Contineum Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Contineum Therapeutics (CTNM)

Contineum Therapeutics, Inc. (CTNM) is developing unique small molecules to combat nerve tissue degeneration, focusing on the rare LPA1R and S1P3R receptors. The quarterly EPS growth trend visualizes the financial dynamics of these developments, where the value of -7.00 reflects this status. Meanwhile, the updated management is successfully adapting internal processes to meet exchange requirements, maintaining investor confidence in the company's scientific potential.

Contineum Therapeutics (CTNM) Earnings per share growth in annualized terms for the last twelve months: for the period 04/06/2024 - 11/18/2026

Analytical breakdowns for Contineum Therapeutics, Inc.

- share price and consensus valuation forecast:
Fundamental company analysis:contineum-tx.com, CTNM
Manufactured product of Contineum Corp

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric allows investors to assess operational efficiency trends and the speed of business scaling. By analyzing the growth rates of quarterly net income per share, one can identify deviations of actual results from market expectations. For Contineum Therapeutics, Inc. (CTNM), this indicator reflects financial stability during the development of drugs against neurodegeneration. A positive trend would confirm the success of the strategy to create agents for myelin protection.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata